{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:57:53Z","timestamp":1781456273083,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.phrs.2026.108252","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:32:39Z","timestamp":1779147159000},"page":"108252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["All screens lead to polo-like kinase 1: A central node in cancer therapeutics and resistance"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-7396","authenticated-orcid":false,"given":"Norah","family":"Al-Souhibani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otilia","family":"Menyhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Dufies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul K.","family":"Siraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratheesh K.","family":"Poyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-2824","authenticated-orcid":false,"given":"Edward","family":"Hitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawla","family":"Al-Kuraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pag\u00e8s","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1003-9788","authenticated-orcid":false,"given":"Khalid S.A.","family":"Khabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.phrs.2026.108252_bib1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1158\/0008-5472.CAN-20-1377","article-title":"PLK1 induces chromosomal instability and overrides cell-cycle checkpoints to drive tumorigenesis","volume":"81","author":"Gheghiani","year":"2021","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.phrs.2026.108252_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070843","article-title":"Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions","volume":"8","author":"Bibi","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2026.108252_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.chembiol.2020.01.007","article-title":"A genetic toggle for chemical control of individual Plk1 substrates","volume":"27","author":"Johnson","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108252_bib4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41417-025-00907-7","article-title":"Structural regulation of PLK1 activity: implications for cell cycle function and drug discovery","volume":"32","author":"Chapagai","year":"2025","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"10.1016\/j.phrs.2026.108252_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s12276-022-00750-y","article-title":"Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108252_bib6","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.E25-02-0053","article-title":"Polo-like kinase 1 maintains transcription and chromosomal accessibility during mitosis","volume":"36","author":"Shen","year":"2025","journal-title":"Mol. Biol. Cell"},{"issue":"9","key":"10.1016\/j.phrs.2026.108252_bib7","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/ncb1767","article-title":"Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression","volume":"10","author":"Fu","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"24","key":"10.1016\/j.phrs.2026.108252_bib8","doi-asserted-by":"crossref","first-page":"25549","DOI":"10.1074\/jbc.M314182200","article-title":"Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation","volume":"279","author":"Ando","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.phrs.2026.108252_bib9","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1128\/MCB.00814-14","article-title":"Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state","volume":"34","author":"Li","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2026.108252_bib10","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10734","article-title":"Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF\/ERK signaling","volume":"5","author":"Wu","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2026.108252_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114747","article-title":"Polo-like kinase 1 (PLK1) signaling in cancer and beyond","volume":"193","author":"Iliaki","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108252_bib12","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/1878-0261.12897","article-title":"Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer","volume":"15","author":"Al-Qahtani","year":"2021","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108252_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2018.3","article-title":"An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma","volume":"118","author":"Linton","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108252_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/0008-5472.CAN-14-2475","article-title":"Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer","volume":"75","author":"Bhola","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108252_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3107","article-title":"Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells","volume":"14","author":"Hu","year":"2012","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108252_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.canlet.2010.01.014","article-title":"Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma","volume":"293","author":"Duan","year":"2010","journal-title":"Cancer Lett."},{"issue":"39","key":"10.1016\/j.phrs.2026.108252_bib17","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1038\/s41388-022-02429-0","article-title":"A high-throughput drug screen reveals means to differentiate triple-negative breast cancer","volume":"41","author":"Vulin","year":"2022","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.phrs.2026.108252_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081117","article-title":"Kinome-Wide Screening with Small Interfering RNA identified polo-like kinase 1 as a key regulator of proliferation in oral cancer cells","volume":"11","author":"Goan","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.phrs.2026.108252_bib19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/0008-5472.CAN-10-2484","article-title":"Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells","volume":"71","author":"Grinshtein","year":"2011","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108252_bib20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41374-019-0247-4","article-title":"Therapeutic potential of PLK1 inhibition in triple-negative breast cancer","volume":"99","author":"Ueda","year":"2019","journal-title":"Lab. Investig."},{"issue":"2","key":"10.1016\/j.phrs.2026.108252_bib21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molonc.2014.10.006","article-title":"Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer","volume":"9","author":"Kappler","year":"2015","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108252_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/neuonc\/noab207","article-title":"A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy","volume":"24","author":"Wang","year":"2022","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108252_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41420-023-01526-7","article-title":"Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma","volume":"9","author":"Wang","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.phrs.2026.108252_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101332","article-title":"PLK1 inhibition-based combination therapies for cancer management","volume":"16","author":"Su","year":"2022","journal-title":"Transl. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108252_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224420","article-title":"Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer","volume":"14","author":"Giordano","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.phrs.2026.108252_bib26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.MCT-15-0897","article-title":"Plk1 inhibitors in cancer therapy: from laboratory to clinics","volume":"15","author":"Gutteridge","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.phrs.2026.108252_bib27","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-10-0095","article-title":"Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability","volume":"9","author":"Degenhardt","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.phrs.2026.108252_bib28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","article-title":"A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene","volume":"137","author":"Luo","year":"2009","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.phrs.2026.108252_bib29","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1158\/1078-0432.CCR-18-3516","article-title":"Polo-like kinase 1 inhibition as a therapeutic approach to selectively target BRCA1-deficient cancer cells by synthetic lethality induction","volume":"25","author":"Carbajosa","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.phrs.2026.108252_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104398","article-title":"AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma","volume":"25","author":"Metselaar","year":"2022","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.phrs.2026.108252_bib31","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1172\/JCI122533","article-title":"PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas","volume":"128","author":"Ren","year":"2018","journal-title":"J. Clin. Invest"},{"issue":"6","key":"10.1016\/j.phrs.2026.108252_bib32","article-title":"Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality","volume":"5","author":"Cunningham","year":"2025","journal-title":"Cell Genom."},{"issue":"20","key":"10.1016\/j.phrs.2026.108252_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cells13201700","article-title":"Polo-like kinase 1 predicts lymph node metastasis in middle eastern colorectal cancer patients; its inhibition reverses 5-Fu resistance in colorectal cancer cells","volume":"13","author":"Poyil","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108252_bib34","article-title":"PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer","volume":"13","author":"Siraj","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108252_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/or.2016.4820","article-title":"Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K\/Akt pathway via Polo-like kinase 1","volume":"36","author":"Mao","year":"2016","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2026.108252_bib36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tranon.2018.04.011","article-title":"Combination of PI3K\/Akt Pathway Inhibition and Plk1 depletion can enhance chemosensitivity to gemcitabine in pancreatic carcinoma","volume":"11","author":"Mao","year":"2018","journal-title":"Transl. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108252_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.molcel.2016.09.016","article-title":"Polo-like kinase-1 regulates myc stabilization and activates a feedforward circuit promoting tumor cell survival","volume":"64","author":"Xiao","year":"2016","journal-title":"Mol. Cell"},{"issue":"20","key":"10.1016\/j.phrs.2026.108252_bib38","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.4161\/cc.9.20.13532","article-title":"p53-dependent repression of polo-like kinase-1 (PLK1)","volume":"9","author":"McKenzie","year":"2010","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.phrs.2026.108252_bib39","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.3109\/10428194.2014.971407","article-title":"The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies","volume":"56","author":"Ward","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2026.108252_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2407-11-71","article-title":"Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice","volume":"11","author":"Ward","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2026.108252_bib41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/1471-2407-12-519","article-title":"MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1","volume":"12","author":"Liu","year":"2012","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2026.108252_bib42","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/ijc.24880","article-title":"Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer","volume":"126","author":"Shi","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2026.108252_bib43","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/cdd.2017.106","article-title":"Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p","volume":"24","author":"Shin","year":"2017","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.phrs.2026.108252_bib44","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/MCB.26.6.2093-2108.2006","article-title":"Normal cells, but not cancer cells, survive severe Plk1 depletion","volume":"26","author":"Liu","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2026.108252_bib45","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.20618","article-title":"PLK1 overexpression as a dual-role biomarker and therapeutic vulnerability in pulmonary adenocarcinoma","volume":"14","author":"You","year":"2026","journal-title":"PeerJ"},{"key":"10.1016\/j.phrs.2026.108252_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70390","article-title":"TNMplot: An enhanced platform for pharmacological target identification through cross-stage and pan-cancer gene expression analysis","author":"Bartha","year":"2026","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108252_bib47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s42003-021-01653-w","article-title":"Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma","volume":"4","author":"Dufies","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.phrs.2026.108252_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.13610","article-title":"-Sobhi, PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects","author":"Poyil","year":"2024","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108252_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16394-2","article-title":"The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation","volume":"7","author":"Smith","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.phrs.2026.108252_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121893","article-title":"Radiosensitization of non-small cell lung cancer cells by the plk1 inhibitor volasertib is dependent on the p53 status","volume":"11","author":"Van den Bossche","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.phrs.2026.108252_bib51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4161\/cc.11.3.19076","article-title":"p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors","volume":"11","author":"Sanhaji","year":"2012","journal-title":"Cell Cycle"},{"issue":"18","key":"10.1016\/j.phrs.2026.108252_bib52","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1080\/15384101.2016.1203493","article-title":"PTEN regulates PLK1 and controls chromosomal stability during cell division","volume":"15","author":"Zhang","year":"2016","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.phrs.2026.108252_bib53","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41467-022-29885-2","article-title":"Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation","volume":"13","author":"He","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108252_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17460441.2023.2159942","article-title":"Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer","volume":"18","author":"Stafford","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108252_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jare.2018.10.002","article-title":"A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening","volume":"16","author":"Abdelfatah","year":"2019","journal-title":"J. Adv. Res."},{"issue":"34","key":"10.1016\/j.phrs.2026.108252_bib56","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2008.16.1547","article-title":"Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors","volume":"26","author":"Mross","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108252_bib57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/bjc.2012.257","article-title":"A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-na\u00efve patients with unresectable exocrine adenocarcinoma of the pancreas \u2013 a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network","volume":"107","author":"Mross","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2026.108252_bib58","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/bjh.15204","article-title":"Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed\/refractory acute myeloid leukaemia","volume":"184","author":"Ottmann","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108252_bib59","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/1535-7163.MCT-11-0765","article-title":"NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies","volume":"11","author":"Valsasina","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"23","key":"10.1016\/j.phrs.2026.108252_bib60","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","article-title":"A Phase Ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"26","author":"Zeidan","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9_ement","key":"10.1016\/j.phrs.2026.108252_bib61","article-title":"Abstract PO1-04-14: PLK1 inhibitor onvansertib extends the response and overcomes resistance to paclitaxel in palbociclib-resistant HR+ breast cancer patient-derived xenografts","volume":"84","author":"Ridinger","year":"2024","journal-title":"Cancer Res."},{"issue":"16_ement","key":"10.1016\/j.phrs.2026.108252_bib62","article-title":"Abstract CT235: A phase 1b\/2 study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC)","volume":"80","author":"Barzi","year":"2020","journal-title":"Cancer Res."},{"issue":"45","key":"10.1016\/j.phrs.2026.108252_bib63","doi-asserted-by":"crossref","first-page":"78452","DOI":"10.18632\/oncotarget.19632","article-title":"Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia","volume":"8","author":"Adachi","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.phrs.2026.108252_bib64","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1021\/cb200551p","article-title":"Enabling and disabling polo-like kinase 1 inhibition through chemical genetics","volume":"7","author":"Burkard","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108252_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112347","article-title":"Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer","volume":"144","author":"Solanes-Casado","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2026.108252_bib66","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809960","article-title":"Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis","volume":"11","author":"Singh","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108252_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010903","article-title":"Genetic enhancers of partial PLK1 inhibition reveal hypersensitivity to kinetochore perturbations","volume":"19","author":"Normandin","year":"2023","journal-title":"PLoS Genet"},{"issue":"10","key":"10.1016\/j.phrs.2026.108252_bib68","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/jid.2015.198","article-title":"Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma","volume":"135","author":"Posch","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108252_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115541","article-title":"PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma","volume":"44","author":"Zhao","year":"2025","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.phrs.2026.108252_bib70","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.21037\/jgo-24-323","article-title":"PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer","volume":"15","author":"Harvey","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.phrs.2026.108252_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117796","article-title":"Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinoma","volume":"182","author":"Kim","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.phrs.2026.108252_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26125708","article-title":"Onvansertib-based second-line therapies in combination with gemcitabine and carboplatin in patient-derived platinum-resistant ovarian carcinomas","volume":"26","author":"Guffanti","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108252_bib73","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fphar.2025.1545038","article-title":"Onvansertib exhibits anti-proliferative and anti-invasive effects in endometrial cancer","volume":"16","author":"Sinha","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108252_bib74","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/1535-7163.MCT-23-0933","article-title":"AKT inhibition sensitizes to polo-like Kinase 1 inhibitor onvansertib in prostate cancer","volume":"23","author":"Nouri","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.phrs.2026.108252_bib75","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41419-024-06894-1","article-title":"Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas","volume":"15","author":"Chiappa","year":"2024","journal-title":"Cell Death Dis."},{"issue":"19","key":"10.1016\/j.phrs.2026.108252_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16193259","article-title":"PLK1 Inhibitor onvansertib enhances the efficacy of alpelisib in PIK3CA-Mutated HR-Positive breast cancer resistant to palbociclib and endocrine therapy: preclinical insights","volume":"16","author":"Sreekumar","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.phrs.2026.108252_bib77","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12964-024-01713-8","article-title":"CRISPR\/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders","volume":"22","author":"Hussen","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"19","key":"10.1016\/j.phrs.2026.108252_bib78","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.7150\/thno.61711","article-title":"The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy","volume":"11","author":"Hagege","year":"2021","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.phrs.2026.108252_bib79","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO-24-01266","article-title":"Onvansertib in combination with chemotherapy and Bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a single-arm, phase II Trial","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.phrs.2026.108252_bib80","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","article-title":"A Phase Ib Study of Onvansertib, a Novel Oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"26","author":"Zeidan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108252_bib81","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2147\/JIR.S347732","article-title":"Pan-Cancer Transcriptomic Analysis Identifies PLK1 crucial for the tumorigenesis of clear cell renal cell carcinoma","volume":"15","author":"Qian","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"15","key":"10.1016\/j.phrs.2026.108252_bib82","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.7150\/ijms.60135","article-title":"PLK1 Inhibition Induces Immunogenic Cell Death and Enhances Immunity against NSCLC","volume":"18","author":"Zhou","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.phrs.2026.108252_bib83","article-title":"Exploration of the combination of PLK1 inhibition with immunotherapy in cancer treatment","author":"Li","year":"2018","journal-title":"J. Oncol. 2018"},{"issue":"8","key":"10.1016\/j.phrs.2026.108252_bib84","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.4161\/cbt.7.8.6220","article-title":"Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy","volume":"7","author":"Mercier","year":"2008","journal-title":"Cancer Biol. Ther."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:22:19Z","timestamp":1781454139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":84,"alternative-id":["S1043661826001672"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108252","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"All screens lead to polo-like kinase 1: A central node in cancer therapeutics and resistance","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108252"}}